SetD7 (Set7/9) is a novel target of PPARγ that promotes the adaptive pancreatic β-cell glycemic response.

Thomas L Jetton, Patricio Flores-Bringas, John L Leahy, Dhananjay Gupta
Author Information
  1. Thomas L Jetton: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  2. Patricio Flores-Bringas: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  3. John L Leahy: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  4. Dhananjay Gupta: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA. Electronic address: dgupta@uvm.edu.

Abstract

Loss of functional pancreatic β-cell mass leads to type 2 diabetes (T2D), attributable to modified β-cell-dependent adaptive gene expression patterns. SetD7 is a histone methyltransferase enriched in pancreatic islets that mono- and dimethylates histone-3-lysine-4 (H3K4), promoting euchromatin modifications, and also maintains the regulation of key β-cell function and survival genes. However, the transcriptional regulation of this important epigenetic modifier is unresolved. Here we identified the nuclear hormone receptor peroxisome proliferator-activated receptor-gamma (PPARγ) as a major transcriptional regulator of SetD7 and provide evidence for direct binding and functionality of PPARγ in the SetD7 promoter region. Furthermore, constitutive shRNA-mediated PPARγ knockdown in INS-1 β-cells or pancreas-specific PPARγ deletion in mice led to downregulation of SetD7 expression as well as its nuclear enrichment. The relevance of the SetD7-PPARγ interaction in β-cell adaptation was tested in normoglycemic 60% partial pancreatectomy (Px) and hyperglycemic 90% Px rat models. Whereas a synergistic increase in islet PPARγ and SetD7 expression was observed upon glycemic adaptation post-60% Px, in hyperglycemic 90% Px rats, islet PPARγ, and PPARγ targets SetD7 and Pdx1 were downregulated. PPARγ agonist pioglitazone treatment in 90% Px rats partially restored glucose homeostasis and β-cell mass and enhanced expression of SetD7 and Pdx1. Collectively, these data provide evidence that the SetD7-PPARγ interaction serves as an important element of the adaptive β-cell response.

Keywords

References

  1. Nature. 2003 Feb 6;421(6923):652-6 [PMID: 12540855]
  2. Mol Cell Biol. 2009 Jul;29(13):3544-55 [PMID: 19414603]
  3. Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E68-73 [PMID: 10893324]
  4. Nat Rev Dis Primers. 2015 Jul 23;1:15019 [PMID: 27189025]
  5. Diabetes. 2007 Jan;56(1):88-95 [PMID: 17192469]
  6. J Biol Chem. 2008 Aug 15;283(33):22612-9 [PMID: 18522939]
  7. Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G319-26 [PMID: 17463185]
  8. J Biol Chem. 2015 Jul 3;290(27):16607-18 [PMID: 25995453]
  9. J Biol Chem. 2013 Aug 30;288(35):25440-25449 [PMID: 23788637]
  10. Dev Cell. 2011 Apr 19;20(4):419-29 [PMID: 21497756]
  11. Cell Metab. 2017 May 2;25(5):1194-1205.e4 [PMID: 28467935]
  12. J Biol Chem. 2015 Apr 10;290(15):9812-22 [PMID: 25713082]
  13. Trends Endocrinol Metab. 2012 Jun;23(6):286-91 [PMID: 22424897]
  14. Diabetes. 2000 Sep;49(9):1517-24 [PMID: 10969836]
  15. Diabetes. 2009 Jan;58(1):185-93 [PMID: 18984737]
  16. Cell Stem Cell. 2018 Mar 1;22(3):428-444.e5 [PMID: 29499155]
  17. Trends Endocrinol Metab. 2021 Jul;32(7):474-487 [PMID: 34030925]
  18. Mol Metab. 2014 Jul 07;3(6):676-80 [PMID: 25161890]
  19. J Clin Invest. 1996 Jan 1;97(1):180-6 [PMID: 8550831]
  20. Epigenetics. 2009 Aug 16;4(6):383-7 [PMID: 19684477]
  21. PLoS One. 2016 Feb 18;11(2):e0149502 [PMID: 26890252]
  22. Mol Cell Biol. 2009 Apr;29(8):2053-67 [PMID: 19237535]
  23. Signal Transduct Target Ther. 2018 Jul 13;3:19 [PMID: 30013796]
  24. Diabetes. 2007 Jun;56(6):1551-8 [PMID: 17360984]
  25. Diabetologia. 2001 Nov;44(11):2056-65 [PMID: 11719838]
  26. Nat Commun. 2018 Feb 2;9(1):485 [PMID: 29396395]
  27. Genes Dev. 2009 Apr 15;23(8):975-85 [PMID: 19390090]
  28. J Biol Chem. 2017 Jul 28;292(30):12449-12459 [PMID: 28487366]
  29. Mol Aspects Med. 2015 Apr;42:19-41 [PMID: 25542976]
  30. Diabetes. 2010 Jun;59(6):1445-50 [PMID: 20332343]
  31. J Biol Chem. 2005 Jul 22;280(29):27466-76 [PMID: 15917242]
  32. Diabetes. 2006 Dec;55(12):3289-98 [PMID: 17130472]
  33. PLoS One. 2013;8(1):e50128 [PMID: 23372643]
  34. EMBO J. 2003 Jan 15;22(2):292-303 [PMID: 12514135]
  35. Mol Endocrinol. 2012 Feb;26(2):257-71 [PMID: 22240811]
  36. J Clin Invest. 2015 Jul 1;125(7):2851-60 [PMID: 26098213]
  37. Diabetes. 2002 Mar;51(3):676-85 [PMID: 11872666]
  38. Islets. 2013 Sep-Dec;5(5):233-7 [PMID: 24356710]
  39. Diabetes. 2013 Nov;62(11):3751-9 [PMID: 23897951]
  40. Diabetes Obes Metab. 2016 Sep;18 Suppl 1:117-22 [PMID: 27615140]
  41. J Clin Invest. 2013 Mar;123(3):1275-84 [PMID: 23434589]
  42. Diabetologia. 2001 Aug;44(8):1026-33 [PMID: 11484081]
  43. Diabetes. 2013 Nov;62(11):3920-6 [PMID: 23863810]
  44. N Engl J Med. 2011 Mar 24;364(12):1104-15 [PMID: 21428766]
  45. J Biol Chem. 2008 Nov 21;283(47):32462-70 [PMID: 18718916]
  46. Genes Dev. 2013 Feb 15;27(4):372-7 [PMID: 23431054]
  47. Islets. 2009 Nov-Dec;1(3):269-72 [PMID: 21099283]
  48. Diabetes Obes Metab. 2016 Sep;18 Suppl 1:78-86 [PMID: 27615135]
  49. Mol Cell Endocrinol. 2008 Nov 6;294(1-2):1-9 [PMID: 18687378]
  50. Diabetes Care. 2014 Jun;37(6):1751-8 [PMID: 24812433]
  51. Cell Stem Cell. 2018 Feb 1;22(2):177-190.e7 [PMID: 29395054]

Grants

  1. R01 DK056818/NIDDK NIH HHS
  2. R56 DK056818/NIDDK NIH HHS

MeSH Term

Animals
Cell Line
Gene Expression Regulation, Enzymologic
Histone-Lysine N-Methyltransferase
Hyperglycemia
Insulin-Secreting Cells
Mice
Mice, Transgenic
PPAR gamma
Rats
Response Elements

Chemicals

PPAR gamma
Pparg protein, mouse
Histone-Lysine N-Methyltransferase
Setd7 protein, mouse
Setd7 protein, rat